Back

Linking serum TTR to patient outcomes in ATTR-CM

17 May 2025 (12:45 - 12:55)
Organised by: Logo
Congress Presentation Part of: ATTRibutes of change: advances in treating and monitoring ATTR-CM Cardiomyopathies HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Laura Obici

I.R.C.C.S. San Matteo Polyclinic, Pavia (Italy)

6 More presentations in this session

Presentation thumbnail
Welcome and introduction
Professor A. Ristic (Belgrade, RS)
Presentation thumbnail
From suspicion to ATTR-CM diagnosis: How do we streamline?
Doctor P. Garcia-Pavia (Majadahonda, ES)
Presentation thumbnail
New therapies for ATTR-CM, new patient expectations
Professor M. Fontana (London, GB)
Presentation thumbnail
Practical insights from ATTR-CM patient cases
Professor C. Tschoepe (Berlin, DE)
Presentation thumbnail
Panel discussion and Q&A

Access the full session

Session thumbnail
ATTRibutes of change: advances in treating and monitoring ATTR-CM
Video

The Event

Event poster

Heart Failure 2025

17 May 2025 12:45 CET
You may be interested in
thumbnail
Congress Presentation
Increase in serum TTR levels observed with acoramidis treatment in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): insights from ATTRibute-CM and its open-label extension
30 August 2024
thumbnail
Congress Session
Cardiac amyloidosis uncovered: from clues to cutting-edge care
17 May 2025
thumbnail
Congress Presentation
Evolving the understanding of TTR's role in health and disease​
31 August 2025
thumbnail
Congress Presentation
Clinical presentation and treatment landscape of patients with transthyretin amyloidosis with cardiomyopathy: a real-world study in five European countries and Japan
18 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources